Premium
A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T‐CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL
Author(s) -
William B.M.,
Abbasi A.,
Huang Y.,
Larbi R.,
Giali R.,
Yang L.,
Brammer J.,
Grantier C.,
Hoffman C.,
Ayyappan S.,
Baiocchi R.,
Epperla N.,
Christian B.,
Alinari L.,
Maddocks K.,
Chung C.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.150_2631
Subject(s) - medicine , brentuximab vedotin , mycosis fungoides , tolerability , lenalidomide , cutaneous t cell lymphoma , peripheral t cell lymphoma , lymphoma , refractory (planetary science) , adverse effect , gastroenterology , oncology , cd30 , t cell , immunology , multiple myeloma , immune system , physics , astrobiology